The solid tumor cancer treatment market size has grown rapidly in recent years. It will grow from $232.2 billion in 2024 to $266.16 billion in 2025 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to advancements in research and development, drug development and approvals, increased cancer incidence rates, growing aging population, patient advocacy and awareness.
The solid tumor cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $442.79 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to personalized medicine trends, immunotherapy advancements, global health challenges and emerging diseases, regulatory frameworks and drug approvals, shifts in healthcare financing and reimbursement models. Major trends in the forecast period include immunotherapy advancements, precision medicine and biomarker identification, combination therapies, digital health integration, technological innovations in treatment modalities.
The rising incidence of cancer is expected to significantly drive the growth of the solid tumor cancer treatment market in the coming years. Cancer is a serious condition characterized by the rapid and uncontrolled reproduction of the body's cells, leading to abnormal growths. Solid tumor cancer treatment refers to therapies aimed at removing solid tumors from the bodies of cancer patients. For example, a report from the World Health Organization, a Switzerland-based international public health agency, indicated that in 2022, nearly 20 million new cancer cases were reported, resulting in approximately 10 million deaths from the disease. Demographic projections suggest that the annual incidence of cancer could reach 35 million by 2050, representing a 77% increase from 2022 levels. Lung cancer was the most frequently diagnosed type, accounting for around 2.5 million new cases, or one in every eight cancers globally, which constitutes 12.4% of all cancers worldwide. Thus, the increasing incidence of cancer is a key factor driving the growth of the solid tumor cancer treatment market.
The growing population is projected to drive the expansion of the solid tumor cancer treatment market in the coming years. An aging population refers to a demographic shift characterized by an increasing proportion of elderly individuals within a society over time. Solid tumor cancer treatment is specifically designed to address the unique challenges and complexities faced by older adults diagnosed with various types of solid tumors. For example, a report from the Population Reference Bureau, a Kenya-based nonprofit organization, noted that the population of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, the share of this age group within the overall population is projected to grow from 17% to 23% during the same timeframe. Therefore, the increasing aging population is a significant factor driving the growth of the solid tumor cancer treatment market.
Innovation in products and treatments has emerged as a notable trend in the solid tumor cancer treatment market, with major companies actively focusing on introducing new solutions to sustain their market positions. An illustrative example is Shanghai Henlius Biotech, a China-based biopharmaceutical company, which launched the PD-1 inhibitor HANSIZHUANG in March 2022. HANSIZHUANG, the company's first innovative monoclonal antibody, was developed for treating adults with advanced, unresectable, or metastatic MSI-H (microsatellite instability - high) solid tumors unresponsive to prior conventional treatments. This product innovation not only provides fresh hope for patients with MSI-H solid tumors but also aligns with the demand for precision immunotherapy, fostering the high-quality development of China's biopharmaceutical industry in the solid tumor cancer treatment market.
Prominent companies in the solid tumor cancer treatment market are directing their focus towards the development of monitoring platforms that leverage tailored tests, including personalized assays, for precise detection. Personalized assays involve customized laboratory tests or analytical procedures designed to examine specific characteristics or markers unique to an individual, often based on their genetic or molecular profile. An exemplary illustration is Invitae, a US-based medical genetics company, which, in collaboration with the Tracerx consortium at University College London, launched a personalized cancer monitoring platform in March 2022. This platform is specifically designed for the detection of minimal or molecular residual disease in patients with solid tumors. Utilizing personalized assays based on the patient's tumor, the platform identifies circulating tumor DNA (ctDNA) in the blood. These assays play a crucial role in helping clinicians assess patient risk, gauge treatment response, and predict the likelihood of recurrence.
In February 2024, AbbVie Inc., a U.S.-based pharmaceutical company, acquired ImmunoGen, Inc. This acquisition is part of AbbVie’s strategy to bolster its oncology capabilities by specifically targeting unmet needs in cancer treatments. The company aims to enhance its solid tumor portfolio and expand its footprint in the oncology market. ImmunoGen, Inc. is a U.S.-based biotechnology firm specializing in the development of antibody-drug conjugate (ADC) therapeutics for cancer treatment.
Major companies operating in the solid tumor cancer treatment market include AstraZeneca plc, Amgen Inc., Bristol Myers Squibb & Company, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Olympus Medical Systems, Astellas Pharma Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Celldex Therapeutics Inc., AbbVie Inc., Bayer AG, Biogen Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Karyopharm Therapeutics Inc., Kyowa Kirin Co. Ltd., MorphoSys AG, Regeneron Pharmaceuticals Inc., Sanofi SA, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Verastem Inc., Zymeworks Inc.
North America was the largest region in the solid tumor cancer treatment market in 2024. The regions covered in the solid tumor cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the solid tumor cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Solid tumor cancer treatment pertains to addressing abnormal tissue masses that typically lack cysts or liquid regions. These tumors encompass various organs such as the brain, ovary, breast, colon, and others. The proliferation of tumor cells is primarily driven by cancer stem cells undergoing division.
The principal treatments for solid tumor cancer encompass chemotherapy, targeted therapy, immunotherapy, hormone therapy, and surgical interventions. Chemotherapy involves drug-based therapies aimed at halting cell division or eliminating cancer cells to impede their growth. Its applications extend across various cancer types such as breast, cervical, colorectal, lung, prostate, among others. These treatments are utilized across diverse end-users such as hospitals, research institutes, and home care settings.
The solid tumor cancer treatment market research report is one of a series of new reports that provides solid tumor cancer treatment market statistics, including solid tumor cancer treatment industry global market size, regional shares, competitors with a solid tumor cancer treatment market share, detailed solid tumor cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the solid tumor cancer treatment industry. This solid tumor cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The solid tumor cancer treatment market includes revenues earned by entities by treat solid tumor cancer through hormonal therapy, targeted drugs, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The solid tumor cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $442.79 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to personalized medicine trends, immunotherapy advancements, global health challenges and emerging diseases, regulatory frameworks and drug approvals, shifts in healthcare financing and reimbursement models. Major trends in the forecast period include immunotherapy advancements, precision medicine and biomarker identification, combination therapies, digital health integration, technological innovations in treatment modalities.
The rising incidence of cancer is expected to significantly drive the growth of the solid tumor cancer treatment market in the coming years. Cancer is a serious condition characterized by the rapid and uncontrolled reproduction of the body's cells, leading to abnormal growths. Solid tumor cancer treatment refers to therapies aimed at removing solid tumors from the bodies of cancer patients. For example, a report from the World Health Organization, a Switzerland-based international public health agency, indicated that in 2022, nearly 20 million new cancer cases were reported, resulting in approximately 10 million deaths from the disease. Demographic projections suggest that the annual incidence of cancer could reach 35 million by 2050, representing a 77% increase from 2022 levels. Lung cancer was the most frequently diagnosed type, accounting for around 2.5 million new cases, or one in every eight cancers globally, which constitutes 12.4% of all cancers worldwide. Thus, the increasing incidence of cancer is a key factor driving the growth of the solid tumor cancer treatment market.
The growing population is projected to drive the expansion of the solid tumor cancer treatment market in the coming years. An aging population refers to a demographic shift characterized by an increasing proportion of elderly individuals within a society over time. Solid tumor cancer treatment is specifically designed to address the unique challenges and complexities faced by older adults diagnosed with various types of solid tumors. For example, a report from the Population Reference Bureau, a Kenya-based nonprofit organization, noted that the population of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, the share of this age group within the overall population is projected to grow from 17% to 23% during the same timeframe. Therefore, the increasing aging population is a significant factor driving the growth of the solid tumor cancer treatment market.
Innovation in products and treatments has emerged as a notable trend in the solid tumor cancer treatment market, with major companies actively focusing on introducing new solutions to sustain their market positions. An illustrative example is Shanghai Henlius Biotech, a China-based biopharmaceutical company, which launched the PD-1 inhibitor HANSIZHUANG in March 2022. HANSIZHUANG, the company's first innovative monoclonal antibody, was developed for treating adults with advanced, unresectable, or metastatic MSI-H (microsatellite instability - high) solid tumors unresponsive to prior conventional treatments. This product innovation not only provides fresh hope for patients with MSI-H solid tumors but also aligns with the demand for precision immunotherapy, fostering the high-quality development of China's biopharmaceutical industry in the solid tumor cancer treatment market.
Prominent companies in the solid tumor cancer treatment market are directing their focus towards the development of monitoring platforms that leverage tailored tests, including personalized assays, for precise detection. Personalized assays involve customized laboratory tests or analytical procedures designed to examine specific characteristics or markers unique to an individual, often based on their genetic or molecular profile. An exemplary illustration is Invitae, a US-based medical genetics company, which, in collaboration with the Tracerx consortium at University College London, launched a personalized cancer monitoring platform in March 2022. This platform is specifically designed for the detection of minimal or molecular residual disease in patients with solid tumors. Utilizing personalized assays based on the patient's tumor, the platform identifies circulating tumor DNA (ctDNA) in the blood. These assays play a crucial role in helping clinicians assess patient risk, gauge treatment response, and predict the likelihood of recurrence.
In February 2024, AbbVie Inc., a U.S.-based pharmaceutical company, acquired ImmunoGen, Inc. This acquisition is part of AbbVie’s strategy to bolster its oncology capabilities by specifically targeting unmet needs in cancer treatments. The company aims to enhance its solid tumor portfolio and expand its footprint in the oncology market. ImmunoGen, Inc. is a U.S.-based biotechnology firm specializing in the development of antibody-drug conjugate (ADC) therapeutics for cancer treatment.
Major companies operating in the solid tumor cancer treatment market include AstraZeneca plc, Amgen Inc., Bristol Myers Squibb & Company, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Olympus Medical Systems, Astellas Pharma Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Celldex Therapeutics Inc., AbbVie Inc., Bayer AG, Biogen Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Karyopharm Therapeutics Inc., Kyowa Kirin Co. Ltd., MorphoSys AG, Regeneron Pharmaceuticals Inc., Sanofi SA, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Verastem Inc., Zymeworks Inc.
North America was the largest region in the solid tumor cancer treatment market in 2024. The regions covered in the solid tumor cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the solid tumor cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Solid tumor cancer treatment pertains to addressing abnormal tissue masses that typically lack cysts or liquid regions. These tumors encompass various organs such as the brain, ovary, breast, colon, and others. The proliferation of tumor cells is primarily driven by cancer stem cells undergoing division.
The principal treatments for solid tumor cancer encompass chemotherapy, targeted therapy, immunotherapy, hormone therapy, and surgical interventions. Chemotherapy involves drug-based therapies aimed at halting cell division or eliminating cancer cells to impede their growth. Its applications extend across various cancer types such as breast, cervical, colorectal, lung, prostate, among others. These treatments are utilized across diverse end-users such as hospitals, research institutes, and home care settings.
The solid tumor cancer treatment market research report is one of a series of new reports that provides solid tumor cancer treatment market statistics, including solid tumor cancer treatment industry global market size, regional shares, competitors with a solid tumor cancer treatment market share, detailed solid tumor cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the solid tumor cancer treatment industry. This solid tumor cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The solid tumor cancer treatment market includes revenues earned by entities by treat solid tumor cancer through hormonal therapy, targeted drugs, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Solid Tumor Cancer Treatment Market Characteristics3. Solid Tumor Cancer Treatment Market Trends and Strategies4. Solid Tumor Cancer Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Solid Tumor Cancer Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Solid Tumor Cancer Treatment Market34. Recent Developments in the Solid Tumor Cancer Treatment Market
5. Global Solid Tumor Cancer Treatment Growth Analysis and Strategic Analysis Framework
6. Solid Tumor Cancer Treatment Market Segmentation
7. Solid Tumor Cancer Treatment Market Regional and Country Analysis
8. Asia-Pacific Solid Tumor Cancer Treatment Market
9. China Solid Tumor Cancer Treatment Market
10. India Solid Tumor Cancer Treatment Market
11. Japan Solid Tumor Cancer Treatment Market
12. Australia Solid Tumor Cancer Treatment Market
13. Indonesia Solid Tumor Cancer Treatment Market
14. South Korea Solid Tumor Cancer Treatment Market
15. Western Europe Solid Tumor Cancer Treatment Market
16. UK Solid Tumor Cancer Treatment Market
17. Germany Solid Tumor Cancer Treatment Market
18. France Solid Tumor Cancer Treatment Market
19. Italy Solid Tumor Cancer Treatment Market
20. Spain Solid Tumor Cancer Treatment Market
21. Eastern Europe Solid Tumor Cancer Treatment Market
22. Russia Solid Tumor Cancer Treatment Market
23. North America Solid Tumor Cancer Treatment Market
24. USA Solid Tumor Cancer Treatment Market
25. Canada Solid Tumor Cancer Treatment Market
26. South America Solid Tumor Cancer Treatment Market
27. Brazil Solid Tumor Cancer Treatment Market
28. Middle East Solid Tumor Cancer Treatment Market
29. Africa Solid Tumor Cancer Treatment Market
30. Solid Tumor Cancer Treatment Market Competitive Landscape and Company Profiles
31. Solid Tumor Cancer Treatment Market Other Major and Innovative Companies
35. Solid Tumor Cancer Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Solid Tumor Cancer Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on solid tumor cancer treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for solid tumor cancer treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The solid tumor cancer treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Chemotherapy; Targeted Therapy; Immunotherapy; Hormone Therapy; Surgical Procedures2) by Application: Breast Cancer; Cervical Cancer; Colorectal Cancer; Lung Cancer; Prostate Cancer; Other Applications
3) by End-Users: Hospitals; Research Institutes; Homecare
Subsegments:
1) by Chemotherapy: Alkylating Agents; Antimetabolites; Anthracyclines; Mitotic Inhibitors2) by Targeted Therapy: Monoclonal Antibodies; Small Molecule Inhibitors; Signal Transduction Inhibitors
3) by Immunotherapy: Checkpoint Inhibitors; CAR T-Cell Therapy; Cancer Vaccines
4) by Hormone Therapy: Aromatase Inhibitors; Anti-Androgens; Selective Estrogen Receptor Modulators (SERMs)
5) by Surgical Procedures: Tumor Resection; Laparoscopic Surgery; Robotic-Assisted Surgery
Key Companies Mentioned: AstraZeneca plc; Amgen Inc.; Bristol Myers Squibb & Company; Eli Lilly & Company; F. Hoffmann-La Roche Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Solid Tumor Cancer Treatment market report include:- AstraZeneca plc
- Amgen Inc.
- Bristol Myers Squibb & Company
- Eli Lilly & Company
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Olympus Medical Systems
- Astellas Pharma Inc.
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Ltd.
- Celldex Therapeutics Inc.
- AbbVie Inc.
- Bayer AG
- Biogen Inc.
- Eisai Co. Ltd.
- Exelixis Inc.
- Genentech Inc.
- Gilead Sciences Inc.
- Incyte Corporation
- Ipsen Biopharmaceuticals Inc.
- Karyopharm Therapeutics Inc.
- Kyowa Kirin Co. Ltd.
- MorphoSys AG
- Regeneron Pharmaceuticals Inc.
- Sanofi SA
- Seattle Genetics Inc.
- Spectrum Pharmaceuticals Inc.
- Taiho Pharmaceutical Co. Ltd.
- Verastem Inc.
- Zymeworks Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 266.16 Billion |
| Forecasted Market Value ( USD | $ 442.79 Billion |
| Compound Annual Growth Rate | 13.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 33 |
